Eisai, Biogen's Alzheimer's med Leqembi wins long-awaited European approval
The drug has hit several roadblocks in its European regulatory journey after its first rejection last July kicked off a stint of back-and-forth decisions.
The drug has hit several roadblocks in its European regulatory journey after its first rejection last July kicked off a stint of back-and-forth decisions.
